Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Huihui Li
Observed names:
Hui-qing Li,
huihui Li
Institutions:
Shandong Tumor Hospital,
Shandong First Medical University
Observed institutions:
Shandong University,
Capital Medical University,
Fred Hutch Cancer Center,
Shandong Tumor Hospital,
Creative Commons,
Beijing Friendship Hospital,
Shandong First Medical University
show all 7
ORCID:
0000-0001-6040-3424
Observed ORCID:
0000-0001-6040-3424
OpenAlex ID:
A5063173355
The decline in the mortality rates of cervical cancer and a plausible explanation in Shandong, China
2000
·
Hui-qing Li
, Shi-quan Jin
, et al.
·
International Journal of Epidemiology
·
41
Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
2022
·
Sha Yin
, Yajing Chi
, et al.
·
Cancer Medicine
·
18
Relationship between fear of progression and symptom burden, disease factors and social/family factors in patients with stage‐IV breast cancer in Shandong, China
2024
·
Qianrun Lu
, Qiuyue Liu
, et al.
·
Cancer Medicine
·
16
PDF
Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study
2023
·
Yajing Chi
, Mu Su
, et al.
·
eLife
·
12
PDF
Cronkhite-Canada syndrome associated with colon cancer metastatic to liver: A case report
2017
·
Jing Wang
, Lei Zhao
, et al.
·
Medicine
·
8
Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study
2024
·
Jie Huang
, Shujuan Sun
, et al.
·
Clinical Breast Cancer
·
7
PDF
Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.
2026
·
Jiong Wu
, Jian Zhang
, et al.
·
Journal of Clinical Oncology
·
6
An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial
2025
·
Jiayu Wang
, Qingyuan Zhang
, et al.
·
癌症:英文版
·
6
PDF
Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study.
2025
·
Shusen Wang
, Qingyuan Zhang
, et al.
·
Journal of Clinical Oncology
·
4
The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
2023
·
Shujuan Sun
, Xiaochu Man
, et al.
·
Cancer Medicine
·
3
Identification of Significant Single‐Nucleotide Polymorphisms Associated With Breast Cancer Recurrence and Metastasis Using GWAS
2025
·
Shujuan Sun
, Sha Yin
, et al.
·
Cancer Innovation
·
2
PDF
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.
2024
·
Yiqun Li
, De Zeng
, et al.
·
Journal of Clinical Oncology
·
1
Author response: Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study
2023
·
Yajing Chi
, Mu Su
, et al.
·
eLife
·
1
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial
2026
·
Jian Zhang
, Quchang Ouyang
, et al.
·
Journal of Clinical Oncology
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial
2026
·
Tiantian Tang
, Jingxuan Wang
, et al.
·
Biomolecules and Biomedicine
PDF
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study
2026
·
Lina Zhang
, Jingxuan Wang
, et al.
·
癌症:英文版
Abstract P5-05-09: Trastuzumab deruxtecan combined with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: an exploratory, multi-center, single-arm, phase Ib/II study (TROPHY)
2025
·
Ying Fan
, Huihui Li
, et al.
·
Clinical Cancer Research
Brain metastasis incidence with bireociclib in HR+/HER2- advanced breast cancer: Pooled analysis of BRIGHT-1 and BRIGHT-2 study.
2025
·
Qingyuan Zhang
, Jiayu Wang
, et al.
·
Journal of Clinical Oncology
PDF
A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer.
2024
·
Xiang Li
, Ying Han
, et al.
·
Journal of Clinical Oncology
PDF
Abstract PO3-06-07: Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
2024
·
huihui Li
, Dongdong Zhou
, et al.
·
Cancer Research
Abstract PO4-04-07: Efficacy, safety and translational study of pyrotinib combined with albumin-bound paclitaxel as firstline treatment of HER-2 positive metastatic breast cancer
2024
·
Huihui Li
, Xiaochu Man
, et al.
·
Cancer Research
Show more works
View as search
Works count:
21
Citation count:
125
H-index:
6
I10-index:
4
Year
Topic
Type